Archive: December, 2012
While we were away, the pharmaceutical industry was involved in two big court decisions, each of which could transform the industry and change how, when, from whom and for what cost Americans get medicine. There was even a slice of the First Amendment in the mix.
One case will be heard by the Supreme Court in this session and the other might be headed there.
As some of you might have read, including in Saturday's Inquirer, the Supreme Court said it would hear arguments in Federal Trade Commission v. Watson Pharmaceuticals, et al., which questions the practice of brand-name companies striking deals with generic companies, which end up delaying potential introduction of cheaper medicine in exchange for dropping suits challenging the viability of patents. These are the so-called pay-to-delay agreements.
Take care and be safe.